Tempus AI is tracking toward full-year profitability metrics for fiscal year 2026, supported by robust revenue guidance scaling between 1.595 billion and 1.605 billion US dollars and a projected positive full-year Adjusted EBITDA of approximately 65 million US dollars. Strong volume growth in its Oncology diagnostics segment and high-margin data licensing partnerships are expected to drive this ongoing financial improvement, marking a significant operational milestone for the healthcare technology enterprise.